Enzyme Replacement Therapy in Orphan and Ultra-Orphan Diseases: The Limitations of Standard Economic Metrics as Exemplified by Fabry-Anderson Disease

Author： Moore David F.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.25, Iss.3, 2007-01, pp. : 201-208

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease

By Beck Michael  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 6, 2002-06 ,pp. : 851-858

Informa Healthcare

Access to resources Recommend Favorite

Enzyme Replacement Therapy in Patients with Fabry's Disease

By Tsuboi K  

The Journal of International Medical Research, Vol. 35, Iss. 4, 2007-07 ,pp. : 574-581

Field House Publishing

Access to resources Recommend Favorite

Fabry disease: recent advances in enzyme replacement therapy

By Germain Dominique P  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 10, 2002-10 ,pp. : 1467-1476

Informa Healthcare

Access to resources Recommend Favorite

Enzyme Replacement Therapy for Fabry Disease: A Systematic Review of Available Evidence

By Schaefer Roland M.  

Drugs, Vol. 69, Iss. 16, 2009-11 ,pp. : 2179-2205

Adis International

Access to resources Recommend Favorite

-Galactosidase replacement therapy in Fabry's disease

By  

Inpharma, Vol. 1, Iss. 1303, 2001-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite